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Summary
Natural killer (NK) cells provide innate defense against
tumors and infections by virtue of potent capacities to
immediately kill cellular targets and produce cyto-
kines. These effector functions may potentially dam-
age normal self-tissues unless they are kept in check
by tolerancemechanisms that need clarification. Here,
we discuss recent studies indicating that the NK cells
acquire functional competence directly through en-
gagement of their MHC-specific receptors by self-
MHC. Ironically, these receptors were first identified
in terms of recognizing target cell MHC class I mole-
cules and inhibiting NK cells in effector responses.
Other studies of NK cell tolerance are also discussed.
Although these studies begin to clarify the means by
which NK cell tolerance is achieved, muchmore inves-
tigation isneededbecauseNKcell tolerance is relevant
to clinical observations in patients with infections and
cancer.
NK cells are bone marrow (BM)-derived lymphocytes,
distinct from T and B cells, that are capable of lysing cer-
tain tumor cells without prior sensitization (Herberman,
1982; Yokoyama, 1999). Because of this intrinsic capac-
ity, termed natural killing, NK cells are thought to serve
as a first line of defense against developing tumor cells.
Over the years, NK cells have been shown to have other
functions. NK cells participate in host responses to cer-
tain intracellular pathogens, including viruses, produce
cytokines that regulate the development of the acquired,
specific immune response, and can reject BM trans-
plants (Bancroft, 1993; Biron et al., 1999; Brown et al.,
2001; Bukowski et al., 1983; Tripp et al., 1993; Yu et al.,
1992). In view of their unusual accumulation at the site
of embryo implantation in the uterus, and at the mater-
nal-fetal interface, NK cells are thought to play an essen-
tial role in maternal tolerance of the fetus (Moffett-King,
2002). More recent studies implicate NK cells in other
pathological processes, including autoimmunity and tis-
sue inflammation (French and Yokoyama, 2004). Due to
their potent innate effector responses, NK cells must be
controlled to avoid inadvertent destruction of normal tis-
sues, i.e., NK cells must be tolerant to normal self. Herein
we will review recent observations that have shed new
light on this important topic.
*Correspondence: yokoyama@im.wustl.eduMissing-Self and Inhibitory Receptors
A defining feature of NK cells is their intrinsic capacity to
react to cellular targets (Lanier et al., 1986), a reaction
that triggers cytokine release as well as target cell cytol-
ysis. NK cell effector functions are regulated by ubiq-
uitously expressed MHC class I (MHC-I) molecules;
targets with normal expression of MHC-I are more resis-
tant to killing than those lacking MHC-I. These findings
form the basis for the ‘‘missing-self’’ hypothesis, postu-
lating that NK cells survey tissues for normal expression
of MHC-I that prevents NK cell activation (Ljunggren and
Karre, 1990). The identification of MHC-I-specific inhibi-
tory receptors expressed on individual NK cells provided
the molecular basis for the MHC-I protective effect
(Colonna and Samaridis, 1995; Karlhofer et al., 1992;
Wagtmann et al., 1995). These receptors contain cyto-
plasmic immunoreceptor tyrosine-based inhibitory mo-
tifs (ITIMs) (Colonna, 1997; Lanier, 1998; Long, 1999;
Moretta et al., 2000; Raulet et al., 2001). Upon ligand
binding, the ITIMs are tyrosine phosphorylated and
then recruit the tyrosine phosphatase SHP-1 that inhibits
NK cell effector responses mediated through their acti-
vation receptors. If unimpeded, the activation receptors
can recognize target cell ligands that result in target lysis
and cytokine secretion. Thus, NK cell inhibitory recep-
tors for target cell MHC-I molecules guide MHC-depen-
dent NK cell specificities for their targets during effector
responses.
Models of NK Cell Tolerance
Although the MHC-specific inhibitory receptors explain
the influence of MHC expression on NK cell effector
functions against target cells, how these receptors are
related to self-tolerance has been a challenging issue.
Several hypotheses have been considered. An individ-
ual NK cell can simultaneously express multiple inhi-
bitory receptors, apparently in a stochastic manner
(Raulet et al., 2001). Some of them may not recognize
self-MHC. However, in the ‘‘at least one receptor
model,’’ as long as each NK cell expresses at least one
receptor with self-MHC-specificity to prevent self-
attack, then the situation is copasetic, according to the
prevailing view (Raulet et al., 2001; Valiante et al.,
1997). Others have suggested that NK cell self-tolerance
may be related to changes in the repertoire of MHC-I-
specific inhibitory receptors, depending on the MHC
haplotype (Raulet et al., 2001; Salcedo et al., 1997; Sent-
man et al., 1995; Valiante et al., 1997). However, there
are only slight differences in the percentage of NK cells
expressing a given NK receptor in different MHC back-
grounds, regardless of whether the receptor is self-
specific or not. There are more impressive and clear-
cut changes in the amount of an NK receptor expressed
on an individual NK cell, as determined by decreased
antibody reactivity, when the host expresses the MHC
ligand for that receptor (Dorfman and Raulet, 1996;
Karlhofer et al., 1994; Olsson et al., 1995). Functional
analyses of NK cells with ‘‘downregulated’’ receptor ex-
pression suggest that such NK cells are more sensitive
to small changes in MHC ligand expression on the
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(Olsson-Alheim et al., 1997; Sentman et al., 1995). How-
ever, these studies involved in vitro conditions that
could alter their intrinsic functional capacities. Thus, it
is still unclear which hypothesis best explains how the
inhibitory receptors are involved in NK cell self-
tolerance.
Unexplained Issues in Self-Tolerance
Although it seemed likely that the MHC-specific inhi-
bitory receptors should be relevant to NK cell self-toler-
ance, this view could not be reconciled with several
fundamental observations. Whereas the missing-self
hypothesis implies that there should be overt NK cell au-
toreactivity in MHC-I-deficient hosts, NK cells are not
spontaneously overactive in humans with MHC-I defi-
ciencies or in mice with deficiency of b2-microglobulin
(b2m) that is required for normal MHC-Ia and -Ib expres-
sion (Bix et al., 1991; Furukawa et al., 1999; Hoglund
et al., 1991; Liao et al., 1991; Vitale et al., 2002). Similar
results were found in mice deficient in transporter asso-
ciated with antigen processing (TAP) genes that are
required for normal MHC-I-peptide loading in the
endoplasmic reticulum (Dorfman et al., 1997; Ljunggren
et al., 1994). Indeed, the opposite was found, i.e., NK
cells from MHC-I-deficient mice demonstrate poor killing
of MHC-I-deficient targets even though they appear
normal in number, tissue distribution, and expression
of activation receptors. Moreover, they cannot reject
MHC-I-deficient BM grafts that are rejected by normal
NK cells. Thus, studies of NK cells from MHC-I-deficient
hosts indicate that NK cells are influenced by the host
MHC-I environment.
Another very difficult issue is related to the 40-year-
old problem of hybrid resistance, whereby host NK cells
in an F1 hybrid animal can reject BM grafts from either in-
bred parent (Bennett, 1987; Cudkowicz and Stimpfling,
1964). Although this is somehow related to missing-
self, it is difficult to understand how NK cells can tell
the difference between cells expressing the full comple-
ment of self-MHC alleles versus those otherwise normal
cells expressing only some self-MHC molecules. Inas-
much as NK cell-mediated rejection of MHC-I-sufficient
BM grafts depends on which host MHC-I allele is pres-
ent (Bennett et al., 1995; Ohlen et al., 1989), NK cells
also are regulated by MHC alleles in the environment,
but how the inhibitory receptors relate to these observa-
tions is not readily explained.
The latter observations relate to another unexplained
issue: the pairing of inhibitory receptors with their cog-
nate MHC ligands. The inhibitory receptors are ex-
pressed by subsets of NK cells apparently in a stochastic
manner and are germline encoded (Raulet et al., 2001;
Trowsdale, 2001; Yokoyama and Plougastel, 2003). Re-
gardless of their structure, i.e., predominantly type I
killer immunoglobulin-like receptors (KIRs) in humans
or lectin-like Ly49 receptors in rodents, it is now clear
that these receptors are highly polymorphic, with multi-
ple haplotypes containing different numbers of encoded
receptors and multiple alleles for each receptor (Makri-
giannis et al., 2002; Vilches and Parham, 2002). More-
over, there may be differences in ligand specificities
for each receptor allele. Importantly, the receptor genes
are located on different chromosomes than the genesfor their highly polymorphic MHC-I ligands, i.e., the re-
ceptor and ligand genes segregate independently.
Thus, there must be mechanisms to provide NK cells
with the appropriate inhibitory receptors with specificity
for self-MHC.
New Observations
The previously described defects in target killing by NK
cells from MHC-deficient hosts (Bix et al., 1991; Furu-
kawa et al., 1999; Hoglund et al., 1991; Vitale et al.,
2002) were difficult to study in greater detail with cellular
targets. The target killing assay generally measures
a summation of individual NK cell responses, and the
universe of NK receptors and their ligands involved in
target recognition remains incompletely defined despite
recent progress. Thus, it was not previously clear if naive
NK cells from MHC-deficient hosts are actually defective
in function or have alterations in target recognition re-
ceptors (Dorfman et al., 1997; Hoglund et al., 1991; Rau-
let et al., 2001; Salcedo et al., 1997).
Recent studies with target cell-free stimulation and
single cell assays of NK cell responsiveness have been
revealing (Fernandez et al., 2005; Kim et al., 2005). Espe-
cially useful was an mAb against NK1.1 (Nkrp1c), an ac-
tivation receptor expressed by all mature and develop-
ing CD32 NK cells in C57BL/6 (B6) mice (Arase et al.,
1996; Colucci et al., 2003; Hackett et al., 1986; Kim et
al., 2002), with intracellular staining for IFNg production
in individual NK cells. We showed that freshly explanted,
resting murine NK cells from wild-type (wt) NK cells
readily produced IFNg in an NK cell autonomous fashion
upon NK1.1 crosslinking (Kim et al., 2005). However, NK
cells displayed almost no IFN-g production when de-
rived from b2m-deficient or KbDb-deficient mice. Similar
results were obtained when NK cells were stimulated
through other activation receptors. Thus, NK cells from
MHC-deficient mice are functionally defective, indicat-
ing that MHC-I influences NK cell functional compe-
tence.
A clue to how MHC influences NK cell functional com-
petence came from studies of MHC-congenic mice
where a correlation was found between the expression
of an inhibitory receptor for self-MHC-I and the capacity
of an individual naive NK cell to be activated to produce
cytokines and kill (Kim et al., 2005). Even though preac-
tivated NK cells were used by others, consistent results
were also described (Fernandez et al., 2005). In C57BL/6
(H2b) mice, cells without expression of known self-re-
ceptors (Ly49C, Ly49I, CD94-NKG2A, CD94-NKG2C,
and CD94-NKG2E) were found to be hyporesponsive
(Fernandez et al., 2005), although it remains possible
that unknown receptors for self could at least partially
account for hyporesponsiveness. Nevertheless, the
data, taken together, suggest the potential involvement
of the MHC-specific receptors in acquisition of func-
tional competence.
More definitive results were obtained by using naive
NK cells from MHC-recombinant congenic and trans-
genic mice (Kim et al., 2005). Particularly informative
were studies with a single chain trimer (SCT) MHC-I mol-
ecule, consisting of antigenic peptide-linker-b2m-linker-
H2Kb heavy chain as a single polypeptide, produced by
the Hansen laboratory (Washington University, St.
Louis), that binds only one NK receptor (Ly49C). In an
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251Figure 1. Licensing of NK Cells by Host MHC-I
This diagram represents a simplified situation where the mouse expresses only one MHC-I molecule, H2Kb, and NK cells express only one MHC-
specific receptor. NK cells expressing Ly49C are licensed because Ly49C recognizes H2Kb during licensing. They are tolerant to self by effector
inhibition through the same receptor-ligand pair involved in licensing. By contrast, NK cells without a self-specific receptor remain unlicensed,
even if they express another MHC-specific receptor, such as Ly49A, because Ly49A does not recognize H2Kb. These unlicensed NK cells do not
require MHC-dependent inhibition to be self-tolerant. cis interactions may play a role in licensing (not shown). Licensing probably occurs during
development, but this needs testing.SCT-Kb transgenic mouse with KbDb and b2m defi-
ciency, only one MHC molecule is expressed and only
Ly49C+ NK cells showed enhanced functional compe-
tence to produce IFN-g over NK cells from KbDb- and
b2m-deficient mice. Thus, NK cells normally acquire
functional competency through their MHC-specific re-
ceptors interacting specifically with host MHC-Ia, a pro-
cess we have termed ‘‘licensing.’’
Significance of New Findings to NK Cell
Self-Tolerance and MHC
We coined the term licensing to indicate that the inhibi-
tory MHC-I-specific receptors, via direct interaction with
MHC-I, participate in acquisition of NK cell functional
competence in order to distinguish this process from
other MHC-dependent education effects. Indeed, other
potential descriptors of licensing, like ‘‘education’’ and
‘‘selection,’’ tend to imply T cell phenomena. NK cells
can be ‘‘licensed to kill’’ if they fulfill certain require-
ments, i.e., MHC-specific NK receptor engagement by
self-MHC-I. In a sense, this is analogous to the licensing
process by which only trained individuals pass require-
ments to drive a car or to practice a profession.
Licensing appears to provide a satisfactory explana-
tion for NK cell self-tolerance as related to self-MHC. It
explains how NK cells acquire functional competenceand how inhibitory receptor and self-MHC are appropri-
ately paired. Licensing should be applicable in any MHC
environment, regardless of which inhibitory receptor is
expressed by an individual NK cell. Licensing may also
be relevant to the ontogenic development of functional
NK cells where gradual acquisition of NK cell function
correlates with Ly49 expression (Dorfman and Raulet,
1998).
The new observations also strongly suggest that there
are two types of self-tolerant NK cells with respect to
host MHC (Figure 1). Under steady-state, noninflamma-
tory conditions in any MHC environment, licensed NK
cells are tolerant because they have inhibitory receptors
for self-MHC, the same receptors involved in licensing.
However, unlicensed NK cells are also tolerant because
they are not functionally competent, and hence, they
have no need for inhibition by self-MHC under steady-
state conditions.
The situation in hosts who are heterozygous for MHC
alleles is somewhat more complex because each MHC
allele could potentially license different NK cell popula-
tions. This aspect of licensing is therefore relevant to hy-
brid resistance because an (A 3 B)F1 hybrid animal
should have NK cells that are separately licensed on dif-
ferent MHC alleles. F1 hybrid NK cells that were licensed
by MHC alleles from parent A should be inhibited by A
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B. The converse should also be true. In the F1 animal it-
self, NK cells are licensed by either parental allele so all
should be inhibited by normal tissues that codominantly
express both MHC alleles. Licensing thus provides an
explanation for how NK cells can tell the difference be-
tween tissues expressing the full complement of MHC al-
leles versus otherwise normal cells expressing only
some alleles. NK cells can therefore be licensed to kill
cells that have downregulated any relevant MHC allele,
as might occur in tumorigenesis or infection. Further
testing of these predictions is warranted.
Possible Mechanisms for Licensing
Although appropriate licensing has a positive outcome,
i.e., the acquisition of functional competence, licensing
does not implicate a specific mechanism. However,
gene transfer studies in which an inhibitory receptor
was transduced into hematopoietic stem cells for BM
reconstitution indicated that licensing requires an intact
cytoplasmic domain, specifically the ITIM (Kim et al.,
2005). Thus, the MHC-specific receptor delivers ITIM-
dependent signals that ultimately result in a licensed
NK cell.
The ITIM recruits SHP-1 that is known to be required
for effector inhibition by Ly49 receptors (Nakamura et
al., 1997). However, SHP-1 is not apparently required
for licensing (Kim et al., 2005), but it cannot be formally
excluded from licensing effects because we studied
mice with a hypomorphic mutant of SHP-1 (mev/v). Al-
though further analysis with complete SHP-1 deficient
mice should be performed, interpretations may be miti-
gated by pleiotropic changes (Shultz, 1988) and the pos-
sible role of SHP-1 in shaping the NK receptor repertoire
or other developmental process (Lowin-Kropf et al.,
2000), independent of licensing per se. The ITIM can re-
cruit other molecules, such as p85a of phophatidylinosi-
tol 3-kinase and SH2-containing inositol phosphatase
(SHIP) (Marti et al., 1998; Wang et al., 2002), but they
do not appear to be relevant to licensing (Kim et al.,
2005). SHP-2 remains a candidate (Yusa and Campbell,
2003; Zhang et al., 2004), but SHP-2-deficiency is em-
bryonic lethal before hematopoiesis occurs (Qu et al.,
2001). Finally, it is possible that the ITIM recruits an as
yet unknown signaling molecule. Nevertheless, the
MHC-specific receptors appear to deliver signals that
are critical to licensing by self-MHC though the nature
of such signals is as yet unknown.
Possible Models for Licensing
Although acquisition of functional competence is a pos-
itive outcome, licensing per se does not explicitly mean
that positive signals are delivered by the self-MHC-spe-
cific receptors. Here, it is important to note that the
MHC-specific receptors could deliver the same signals
in licensing and in effector inhibition. On the other
hand, the receptors could deliver qualitatively or quanti-
tatively different signals during either process. This is
not unprecedented, as the same T cell receptor could in-
duce negative or positive selection, activation or anergy,
for example (Starr et al., 2003). Context, signaling milieu,
and other factors play important roles in determining
such outcomes, perhaps not too different from NK cell
licensing versus effector inhibition. Thus, to reiterate, li-censing gives rise to a positive functional outcome, but
the nature of the signal delivered by the MHC-specific
receptor remains to be determined.
At least two qualitatively different models can thus be
considered (Figure 2). Perhaps the simplest model is
that the MHC-specific receptor confers licensing di-
rectly by itself (model A, stimulatory model). This could
be due to delivery of signals that directly induce a differ-
entiation process and license NK cells.
Another model for how the MHC-specific receptors li-
cense NK cells is consistent with its inhibitory function in
effector responses (Figure 2). In model B (inhibitory
model), the MHC-specific receptors could mediate li-
censing by decreasing the effect of an activation recep-
tor. In such a model, it is necessary to postulate that ac-
quisition of NK cell function is strongly affected by
signals from an as yet uncharacterized activation recep-
tor for self. When unimpeded by self-MHC-I, the NK cell
may become hyporesponsive due to overstimulation
through the activation receptor. The inhibitory receptors
provide self-MHC specificity by engaging self-MHC,
thereby downregulating the action of the activation re-
ceptor and allowing functional competence on self-spe-
cific NK cells to be displayed. This model is somewhat
akin to T cell anergy and is favored by Fernandez et al.
(2005).
Although both models are similar to those previously
proposed (Wu and Raulet, 1997), we now know that en-
gagement of the MHC-specific receptor with self-MHC
is a required key step (Kim et al., 2005) and is common
to both models. Also, the models are not mutually exclu-
sive, as there could be elements of both. Because li-
censing apparently requires some element of MHC-I-
specific receptor signaling, it is also possible that sig-
nals could be modulated in either model. For example,
coreceptors or adhesion molecules may be needed re-
gardless of the type of signal delivered during licensing.
These possible effects could account for the observa-
tion that not all NK cells with a given self-specific recep-
tor are triggered during activation receptor crosslinking
(Kim et al., 2005).
Regardless of how the inhibitory receptors lead to li-
censing, quantitative issues, i.e., signal strength, may
apply. The functional competence of NK cells may be
enhanced if they had been licensed through more than
one receptor, i.e., NK cells licensed through two inhibi-
tory receptors for self may be more potent than when li-
censed through either receptor alone. Related to this,
NK cells with a given receptor may be more potent effec-
tors if the receptor interacts with a higher-affinity self-
MHC ligand than if it binds a self-ligand of lower affinity.
Similarly, avidity issues may apply if the host is homo- or
heterozygous for MHC alleles recognized by a given re-
ceptor. In addition, the frequency and extent of interac-
tions may be relevant. Consistent with these possibili-
ties, the potency of NK cells appears to depend on
which MHC allele and how many alleles are present in
the host (Johansson et al., 2005). Conversely, it is possi-
ble that in some circumstances, NK cells do not receive
a strong enough signal from self-MHC to become li-
censed. For example, MHC-I levels might be too low or
the receptors may bind some MHC alleles with too low
an affinity for licensing to occur. Thus, signal strength is-
sues need to be considered.
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MHC-Specific Receptors during Licensing
The MHC-specific receptors are directly in-
volved by engaging host MHC-I and deliver-
ing signals that result in licensed NK cells.
Two simple models are depicted to illustrate
how signaling through the MHC-specific re-
ceptor could result in licensed cells. In model
A (stimulatory model), the MHC-specific re-
ceptor directly delivers stimulatory signals
that result in licensed NK cells. In model B
(inhibitory model), there is an activation re-
ceptor that engages a self-ligand. Without
MHC-specific receptor engagement, there
is a hyporesponsive state (not shown). If
the MHC-specific receptor is also engaged,
it delivers signals that inhibit otherwise unre-
strained activation receptor signaling, allow-
ing licensing to proceed as shown. Regard-
less of which model is correct, engagement
of the MHC-specific receptor and subse-
quent signaling are required for acquisition
of NK cell functional competence. In addi-
tion, cis interactions between an NK cell re-
ceptor and self-MHC-I (not shown) may
have effects.There are several published observations that should
be considered in analysis of the two licensing models
(Figure 2). In C57BL/6 mice with mosaic expression
(some cells express transgene, some do not) of an
H2Dd transgene (Johansson et al., 1997), there is no ap-
parent autoreactivity against cells lacking transgene ex-
pression. Furthermore, the mosaic transgenic mice
were able to accept BM from either C57BL/6 or another
C57BL/6 mouse with full expression of transgenic H2Dd
even though hybrid resistance studies would have pre-
dicted rejection. Related results were observed in irradi-
ated chimeric mice reconstituted with BM cells from ei-
ther wt C57BL/6, b2m-deficient, or mixed BM from both
donors (Wu and Raulet, 1997). Wt NK cells were com-
promised in their ability to subsequently reject b2m-de-
ficient BM when they developed in b2m-deficient hosts.
When mixed BM chimeras were used, they were also
compromised in ability to reject b2m-deficient BM re-
gardless of whether or not the host was b2m deficient.
These studies were interpreted as demonstrating a dom-
inant effect of MHC-I deficiency in producing hypores-
ponsiveness, thereby supporting the concept that NK
cell maturation involves the action of a self-specific ac-
tivation receptor (Fernandez et al., 2005; Wu and Raulet,
1997) and therefore compatible with model B and not
model A (Figure 2).
On the other hand, the mixed BM chimera and mosaic
transgenic mouse data appear to be inconclusive. The
ability to reject b2m-deficient BM in the mixed BM chi-
meras was intermediate in MHC-sufficient hosts (Wu
and Raulet, 1997) and, thus, can be interpreted from ei-
ther a glass half-empty (hyporesponsive in terms of re-
jection) or glass half-full perspective (acquisition of
rejection). The capacity of NK cells to reject BM is sensi-
tive to BM dosage, so more careful BM dose titrations
are needed for appropriate interpretations. BM dosetitrations are similarly required for the mosaic transgenic
mice studies (Johansson et al., 1997). Moreover, expres-
sion of the transgenic MHC molecule was not reported
except for splenocytes. Because the relevant host tis-
sue expressing self-MHC and the contribution of other
factors for licensing are not yet known, further analysis
of the mosaic transgenic mice may be insightful for un-
derstanding licensing requirements.
Even if the aforementioned studies are validated with
further testing, other considerations apply. Because an
interaction between MHC-specific receptor and its cog-
nate self-MHC ligand is required, it is possible that the
mixed BM and mosaic MHC transgenic mice do not de-
liver a strong enough signal for licensing to occur, re-
gardless of the type of signal. If MHC-I in either system
was unable to deliver a strong enough signal then licens-
ing of at least some cells would fail, and then they would
appear unresponsive, akin to unlicensed NK cells. Re-
lated to this is the recent observation that Ly49 recep-
tors can interact with their MHC-I ligand on the cell sur-
face of the NK cell itself (Doucey et al., 2004). This cis
interaction also appears to be related to the apparent
downregulation of receptor expression as gauged by
anti-Ly49 mAb reactivity, a long noted phenomenon
(Karlhofer et al., 1994). With our SCT-Kb transgenic
mice expressing only one MHC-I molecule, the only re-
ceptor displaying downregulation was Ly49C, and fur-
thermore, transgenic SCT-Kb expression resulted in an
inability of H2Kb tetramers to bind Ly49C, indicating
that cis interactions do occur on primary NK cells
in vivo (Kim et al., 2005) These cis interactions could
contribute to receptor strength issues and provide an-
other possible explanation for the effects in the mixed
BM and mosaic MHC transgenic mice. For example,
NK cells from the mosaic MHC transgenic mouse that
expressed H2Dd were much better at killing than those
Immunity
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much the extent of receptor engagement contributes
to licensing and NK cell tolerance requires further inves-
tigation. Thus, at the moment, the available data do not
distinguish between either model A or B (Figure 2).
Other Considerations
At the moment, self-specific NK cell activation receptors
are not well characterized. One such receptor for MHC-I
is potentially the Ly49D activation receptor that has
been reported to functionally recognize H2Dd and acti-
vate NK cell killing (Nakamura et al., 1999). However,
physical interaction of Ly49D with H2Dd has not yet
been described, and Ly49D function in the context of
self-H2Dd has not been studied in detail. Licensing
should also be discussed with respect to NKG2D, a cos-
timulatory receptor on mouse and human NK cells and
a primary activation receptor on mouse NK cells during
certain circumstances (Cerwenka et al., 2000; Diefen-
bach et al., 2000; Diefenbach et al., 2002; Gilfillan et al.,
2002; Groh et al., 2001; Ho et al., 2002). Ligands for
NKG2D are constitutively expressed at low levels but
can be markedly upregulated during stress, such as in
response to DNA damage (Gasser et al., 2005). This li-
gand induction can shift the balance of activation and in-
hibitory receptor function to activation, according to the
induced-self model (Diefenbach and Raulet, 2003). How-
ever, unlicensed NK cells cannot kill YAC-1 targets well
(Liao et al., 1991), even though YAC-1 expresses several
ligands for NKG2D (Cerwenka et al., 2000; Diefenbach et
al., 2000), suggesting that licensing affects the capacity
of NK cells to respond to induced-self ligands.
Transgenic mice have been produced that constitu-
tively express NKG2D ligands, allowing analysis of NK
cells that are presumably chronically stimulated. Al-
though studies have not been reported on the outcome
of MHC-I-deficiency in these mice, in one case, NKG2D
signaling is downregulated in a mechanism that ap-
peared to be selective for NKG2D (Wiemann et al.,
2005), whereas in another, NK cell function appeared
to be more broadly perturbed (Oppenheim et al., 2005).
Thus, the potential effect of chronic activation receptor
engagement and their relationship to licensing requires
further analysis.
In addition to MHC-I-dependent inhibition, NK cells
can also be inhibited by non-MHC ligands; several inhib-
itory receptors and their non-MHC ligands have been re-
cently identified (Aldemir et al., 2005; Castells et al.,
2001; Iizuka et al., 2003; Kumar and McNerney, 2005;
Lee et al., 2004; Rosen et al., 2005). Some of these recep-
tors have a striking resemblance to the MHC-I-specific
inhibitory receptors in structure and ITIM-dependent in-
hibition. In addition, there are many orphan receptors
that are likely to be inhibitory because they have canon-
ical ITIMs in their cytoplasmic domains (Long, 1999).
Thus, it will be interesting to determine how they contrib-
ute to NK cell tolerance in general and if these receptors
contribute to functional maturation of NK cells in a man-
ner analogous to MHC-dependent licensing.
Related to this last point, there are many other ITIM-
bearing receptors encoded in the genome (Long, 1999).
Although many remain as orphan receptors because
their ligands and physiological roles are unknown, per-
haps these receptors have non-MHC ligands and arealso relevant to licensing of NK cells. Regardless of their
ligands, they could contribute to MHC-dependent li-
censing in a manner analogous to the engagement of
multiple NK receptors on an individual NK cell as dis-
cussed in the signal strength concept above. Moreover,
these receptors may play a cell differentiation role by
themselves on non-NK cells.
There appear to be a number of unlicensed NK cells
in normal naive mice. Clues to their physiological role
may come from observations indicating that the require-
ment for self-MHC recognition in licensing functional
competence can be overcome by prior NK cell stimula-
tion (Kim et al., 2005). Defects in the activation of NK
cells from MHC-I-deficient mice were not evident when
NK cells were stimulated nonspecifically with phorbol
ester and ionomycin, which activate at a postreceptor
level. Moreover, the differential activation of NK cells
from MHC-sufficient and MHC-deficient hosts was less
pronounced when the NK cells were prestimulated
with poly-I:C or IL-2, suggesting that the cytokine milieu
could also affect licensing requirements.
Unlicensed NK cells may have an important role dur-
ing inflammatory conditions. Indeed, most if not all NK
cells can be activated during systemic viral infections
(Dokun et al., 2001; Wang et al., 2000), and this may be
relevant to absence of functional defects in controlling
systemic infections by MHC-deficient mice (Fernandez
et al., 2005; Tay et al., 1995). Furthermore, stimulation
of plasmacytoid dendritic cells through Toll-like recep-
tor 9 and MyD88 is required for efficient viral clearance
by NK cells (Krug et al., 2004). Thus, under certain cir-
cumstances, unlicensed NK cells may play an important
role in host defense against systemic infections and per-
haps even against tumors, areas that require further
evaluation.
Licensing of Human NK Cells
Whether or not licensing applies to human NK cells
needs to be established, but there are several parallels
with mice, including polymorphic receptors and HLA li-
gands encoded on different chromosomes, and MHC-
deficient humans have NK cell defects (Furukawa et
al., 1999; Zimmer et al., 1998). Thus, there must be
mechanisms to account for appropriate pairing of hu-
man KIRs with their cognate ligands and licensing could
achieve this end.
Importantly, combinations of certain KIR genotypes
with HLA genotypes appear to influence certain clinical
outcomes in humans (Martin and Carrington, 2005), sug-
gesting that functional interactions between KIRs and
their HLA ligands could occur. In particular, licensing
of human NK cells may be relevant to recent clinical ob-
servations in patients with viral infections (Carrington et
al., 2005; Khakoo et al., 2004; Martin et al., 2002). For ex-
ample, hepatitis C virus (HCV) can cause a chronic, per-
sistent infection, whereas other patients resolve the in-
fection. Interestingly, patients who are homozygous for
a KIR gene (KIR2DL3) are more likely to clear HCV if
they are also homozygous for the HLA-C alleles recog-
nized by KIR2DL3 (Khakoo et al., 2004). In infections
with papillomavirus that can go on to produce cervical
carcinomas, resistance to developing neoplasia was
similarly associated with specific inhibitory KIR and
HLA genotypes (Carrington et al., 2005). Again,
Review
255protection was best associated with genes encoding
certain KIR-HLA receptor-ligand pairs.
If human NK cells are licensed through KIR interac-
tions with HLA, then perhaps licensing may be relevant
to infection outcomes. Related to the signal strength
concept discussed above, certain KIR receptor and
HLA ligand combinations could be especially potent in
licensing human NK cells and perhaps homozygosity
may be similarly explained. Alternatively, some viruses
are known to downregulate certain HLA alleles better
than others (Tortorella et al., 2000). Selective downregu-
lation may then permit attack only by NK cells that were
licensed by the same HLA molecule. Thus, these intrigu-
ing studies imply a functional interaction between KIRs
and cognate HLA ligands that may be related to licens-
ing, issues that require further testing.
In BM transplantation for leukemia, donor NK cells
may help provide an antileukemia effect against residual
malignant cells in the recipient if there is a mismatch be-
tween the donor and recipient HLA alleles (Ruggeri et al.,
2002). However, this observation has not been uniformly
observed in other transplant centers (Davies et al., 2002;
Hsu et al., 2005; Parham and McQueen, 2003). Licensing
predicts that both donor KIR and HLA alleles need to be
considered in terms of whether or not the donor NK cells
express receptors allowing licensing by donor HLA al-
leles and if these licensed donor NK cells are then not in-
hibited by HLA alleles in the recipient. If cis and trans in-
teractions also apply to these structurally distinct
receptors, then they also need to be considered in the
BMT situation.
Concluding Remarks
Although it will be challenging to uncover further details
of licensing, it provides potentially unifying explanations
for many observed aspects of MHC-dependent NK cell
tolerance, including pairing of receptor and self-MHC li-
gand, impaired NK cell activity in naive MHC-deficient
hosts, and how receptors with inhibitory function in ef-
fector responses guide acquisition of NK cell tolerance.
It may also provide a satisfactory explanation for hybrid
resistance. How licensing is related to NK cell immune
responses in infection and cancer needs to be better un-
derstood because licensing may be relevant to clinical
outcomes. Finally, it remains possible that additional
NK cell tolerance mechanisms are yet to be discovered,
as non-MHC-specific receptors and other observations
are just beginning to be characterized. Clearly more
work in this area is needed.
Acknowledgments
We apologize to colleagues whose work was not cited due to space
constraints or our inadvertent omission. We thank John Sunwoo for
thoughtful discussions and critically reading this manuscript and
past and present members of our laboratory for their contributions.
We especially thank Ted Hansen and his laboratory for allowing us to
work on their otherwise unpublished transgenic mice. Work in the
Yokoyama laboratory is supported by the Howard Hughes Medical
Institute, Barnes-Jewish Hospital Foundation, and grants from the
National Institutes of Health.
References
Aldemir, H., Prod’homme, V., Dumaurier, M.J., Retiere, C., Poupon,
G., Cazareth, J., Bihl, F., and Braud, V.M. (2005). Cutting edge: lectin-like transcript 1 is a ligand for the CD161 receptor. J. Immunol. 175,
7791–7795.
Arase, H., Arase, N., and Saito, T. (1996). Interferon gamma produc-
tion by natural killer (NK) cells and NK1.1+ T cells upon NKR-P1
cross-linking. J. Exp. Med. 183, 2391–2396.
Bancroft, G.J. (1993). The role of natural killer cells in innate resis-
tance to infection. Curr. Opin. Immunol. 5, 503–510.
Bennett, M. (1987). Biology and genetics of hybrid resistance. Adv.
Immunol. 41, 333–445.
Bennett, M., Yu, Y.Y., Stoneman, E., Rembecki, R.M., Mathew, P.A.,
Lindahl, K.F., and Kumar, V. (1995). Hybrid resistance: ‘negative’ and
‘positive’ signaling of murine natural killer cells. Semin. Immunol. 7,
121–127.
Biron, C.A., Nguyen, K.B., Pien, G.C., Cousens, L.P., and Salazar-
Mather, T.P. (1999). Natural killer cells in antiviral defense: function
and regulation by innate cytokines. Annu. Rev. Immunol. 17, 189–
220.
Bix, M., Liao, N.S., Zijlstra, M., Loring, J., Jaenisch, R., and Raulet, D.
(1991). Rejection of class I MHC-deficient haemopoietic cells by irra-
diated MHC-matched mice. Nature 349, 329–331.
Brown, M.G., Dokun, A.O., Heusel, J.W., Smith, H.R., Beckman, D.L.,
Blattenberger, E.A., Dubbelde, C.E., Stone, L.R., Scalzo, A.A., and
Yokoyama, W.M. (2001). Vital involvement of a natural killer cell ac-
tivation receptor in resistance to viral infection. Science 292, 934–
937.
Bukowski, J.F., Woda, B.A., Habu, S., Okumura, K., and Welsh, R.M.
(1983). Natural killer cell depletion enhances virus synthesis and
virus-induced hepatitis in vivo. J. Immunol. 131, 1531–1538.
Carrington, M., Wang, S., Martin, M.P., Gao, X., Schiffman, M.,
Cheng, J., Herrero, R., Rodriguez, A.C., Kurman, R., Mortel, R.,
et al. (2005). Hierarchy of resistance to cervical neoplasia mediated
by combinations of killer immunoglobulin-like receptor and human
leukocyte antigen loci. J. Exp. Med. 201, 1069–1075.
Castells, M.C., Klickstein, L.B., Hassani, K., Cumplido, J.A., Lacou-
ture, M.E., Austen, K.F., and Katz, H.R. (2001). gp49B1-alpha(v)-
beta3 interaction inhibits antigen-induced mast cell activation.
Nat. Immunol. 2, 436–442.
Cerwenka, A., Bakker, A.B.H., McClanahan, T., Wagner, J., Wu, J.,
Phillips, J.H., and Lanier, L.L. (2000). Retinoic acid early inducible
genes define a ligand family for the activating NKG2D receptor in
mice. Immunity 12, 721–727.
Colonna, M. (1997). Specificity and function of immunoglobulin su-
perfamily NK cell inhibitory and stimulatory receptors. Immunol.
Rev. 155, 127–133.
Colonna, M., and Samaridis, J. (1995). Cloning of immunoglobulin-
superfamily members associated with HLA-C and HLA-B recogni-
tion by human natural killer cells. Science 268, 367–368.
Colucci, F., Caligiuri, M.A., and Di Santo, J.P. (2003). What does it
take to make a natural killer? Nat. Rev. Immunol. 3, 413–425.
Cudkowicz, G., and Stimpfling, J.H. (1964). Hybrid resistance to pa-
rental marrow grafts: association with the K region of H-2. Science
144, 1339–1340.
Davies, S.M., Ruggieri, L., DeFor, T., Wagner, J.E., Weisdorf, D.J.,
Miller, J.S., Velardi, A., and Blazar, B.R. (2002). Evaluation of KIR li-
gand incompatibility in mismatched unrelated donor hematopoietic
transplants. Killer immunoglobulin-like receptor. Blood 100, 3825–
3827.
Diefenbach, A., Jamieson, A.M., Liu, S.D., Shastri, N., and Raulet,
D.H. (2000). Ligands for the murine NKG2D receptor: expression
by tumor cells and activation of NK cells and macrophages. Nat. Im-
munol. 1, 119–126.
Diefenbach, A., and Raulet, D.H. (2003). Innate immune recognition
by stimulatory immunoreceptors. Curr. Opin. Immunol. 15, 37–44.
Diefenbach, A., Tomasello, E., Lucas, M., Jamieson, A.M., Hsia, J.K.,
Vivier, E., and Raulet, D.H. (2002). Selective associations with signal-
ing molecules determine stimulatory versus costimulatory activity of
NKG2D. Nat. Immunol. 3, 1142–1149.
Dokun, A.O., Kim, S., Smith, H.R., Kang, H.S., Chu, D.T., and Yo-
koyama, W.M. (2001). Specific and nonspecific NK cell activation
during virus infection. Nat. Immunol. 2, 951–956.
Immunity
256Dorfman, J.R., and Raulet, D.H. (1996). Major histocompatibility
complex genes determine natural killer cell tolerance. Eur. J. Immu-
nol. 26, 151–155.
Dorfman, J.R., and Raulet, D.H. (1998). Acquisition of Ly49 receptor
expression by developing natural killer cells. J. Exp. Med. 187, 609–
618.
Dorfman, J.R., Zerrahn, J., Coles, M.C., and Raulet, D.H. (1997). The
basis for self-tolerance of natural killer cells in beta2-microglobulin-
and TAP-1- mice. J. Immunol. 159, 5219–5225.
Doucey, M.A., Scarpellino, L., Zimmer, J., Guillaume, P., Luescher,
I.F., Bron, C., and Held, W. (2004). Cis association of Ly49A with
MHC class I restricts natural killer cell inhibition. Nat. Immunol. 5,
328–336.
Fernandez, N.C., Treiner, E., Vance, R.E., Jamieson, A.M., Lemieux,
S., and Raulet, D.H. (2005). A subset of natural killer cells achieves
self-tolerance without expressing inhibitory receptors specific for
self-MHC molecules. Blood 105, 4416–4423.
French, A.R., and Yokoyama, W.M. (2004). Natural killer cells and au-
toimmunity. Arthritis Res. Ther. 6, 8–14.
Furukawa, H., Yabe, T., Watanabe, K., Miyamoto, R., Miki, A., Akaza,
T., Tadokoro, K., Tohma, S., Inoue, T., Yamamoto, K., and Juji, T.
(1999). Tolerance of NK and LAK activity for HLA class I-deficient tar-
gets in a TAP1-deficient patient (bare lymphocyte syndrome type I).
Hum. Immunol. 60, 32–40.
Gasser, S., Orsulic, S., Brown, E.J., and Raulet, D.H. (2005). The DNA
damage pathway regulates innate immune system ligands of the
NKG2D receptor. Nature 436, 1186–1190.
Gilfillan, S., Ho, E.L., Cella, M., Yokoyama, W.M., and Colonna, M.
(2002). NKG2D recruits two distinct adapters to trigger natural killer
cell activation and costimulation. Nat. Immunol. 3, 1150–1155.
Groh, V., Rhinehart, R., Randolph-Habecker, J., Topp, M.S., Riddell,
S.R., and Spies, T. (2001). Costimulation of CD8ab T cells by NKG2D
via engagement by MIC induced on virus-infected cells. Nat. Immu-
nol. 2, 255–260.
Hackett, J., Jr., Tutt, M., Lipscomb, M., Bennett, M., Koo, G., and Ku-
mar, V. (1986). Origin and differentiation of natural killer cells. II.
Functional and morphologic studies of purified NK-1.1+ cells. J. Im-
munol. 136, 3124–3131.
Herberman, R. (1982). NK Cells and Other Natural Effector Cells
(New York: Academic Press).
Ho, E.L., Carayannopoulos, L.N., Poursine-Laurent, J., Kinder, J.,
Plougastel, B., Smith, H.R.C., and Yokoyama, W.M. (2002). Co-stim-
ulation of multiple NK cell activation receptors by NKG2D. J. Immu-
nol. 169, 3667–3675.
Hoglund, P., Ohlen, C., Carbone, E., Franksson, L., Ljunggren, H.G.,
Latour, A., Koller, B., and Ka¨rre, K. (1991). Recognition of beta 2-mi-
croglobulin- negative (beta 2m-) T-cell blasts by natural killer cells
from normal but not from beta 2m- mice: nonresponsiveness con-
trolled by beta 2m- bone marrow in chimeric mice. Proc. Natl.
Acad. Sci. USA 88, 10332–10336.
Hsu, K.C., Keever-Taylor, C.A., Wilton, A., Pinto, C., Heller, G., Arkun,
K., O’Reilly, R.J., Horowitz, M.M., and Dupont, B. (2005). Improved
outcome in HLA-identical sibling hematopoietic stem-cell transplan-
tation for acute myelogenous leukemia predicted by KIR and HLA
genotypes. Blood 105, 4878–4884.
Iizuka, K., Naidenko, O.V., Plougastel, B.F., Fremont, D.H., and Yo-
koyama, W.M. (2003). Genetically linked C-type lectin-related li-
gands for the NKRP1 family of natural killer cell receptors. Nat. Im-
munol. 4, 801–807.
Johansson, M.H., Bieberich, C., Jay, G., Karre, K., and Hoglund, P.
(1997). Natural killer cell tolerance in mice with mosaic expression
of major histocompatibility complex class I transgene. J. Exp.
Med. 186, 353–364.
Johansson, S., Johansson, M., Rosmaraki, E., Vahlne, G., Mehr, R.,
Salmon-Divon, M., Lemonnier, F., Karre, K., and Hoglund, P. (2005).
Natural killer cell education in mice with single or multiple major his-
tocompatibility complex class I molecules. J. Exp. Med. 201, 1145–
1155.Karlhofer, F.M., Ribaudo, R.K., and Yokoyama, W.M. (1992). MHC
class I alloantigen specificity of Ly-49+ IL-2-activated natural killer
cells. Nature 358, 66–70.
Karlhofer, F.M., Hunziker, R., Reichlin, A., Margulies, D.H., and Yo-
koyama, W.M. (1994). Host MHC class I molecules modulate
in vivo expression of a NK cell receptor. J. Immunol. 153, 2407–2416.
Khakoo, S.I., Thio, C.L., Martin, M.P., Brooks, C.R., Gao, X., Astem-
borski, J., Cheng, J., Goedert, J.J., Vlahov, D., Hilgartner, M., et al.
(2004). HLA and NK cell inhibitory receptor genes in resolving hepa-
titis C virus infection. Science 305, 872–874.
Kim, S., Iizuka, K., Kang, H.S., Dokun, A., French, A.R., Greco, S.,
and Yokoyama, W.M. (2002). In vivo developmental stages in murine
natural killer cell maturation. Nat. Immunol. 3, 523–528.
Kim, S., Poursine-Laurent, J., Truscott, S.M., Lybarger, L., Song,
Y.J., Yang, L., French, A.R., Sunwoo, J.B., Lemieux, S., Hansen,
T.H., and Yokoyama, W.M. (2005). Licensing of natural killer cells
by host major histocompatibility complex class I molecules. Nature
436, 709–713.
Krug, A., French, A.R., Barchet, W., Fischer, J.A.A., Dzionek, A., Pin-
gel, J.T., Orihuela, M.M., Akira, S., Yokoyama, W.M., and Colonna,
M. (2004). TLR9-dependent recognition of MCMV by IPC and DC
generates coordinated cytokine responses that activate antiviral
NK cell function. Immunity 21, 107–119.
Kumar, V., and McNerney, M.E. (2005). A new self: MHC-class-I-
independent natural-killer-cell self-tolerance. Nat. Rev. Immunol.
5, 363–374.
Lanier, L.L. (1998). NK cell receptors. Annu. Rev. Immunol. 16, 359–
393.
Lanier, L.L., Phillips, J.H., Hackett, J., Jr., Tutt, M., and Kumar, V.
(1986). Natural killer cells: definition of a cell type rather than a func-
tion. J. Immunol. 137, 2735–2739.
Lee, K.M., McNerney, M.E., Stepp, S.E., Mathew, P.A., Schatzle,
J.D., Bennett, M., and Kumar, V. (2004). 2B4 acts as a non-major his-
tocompatibility complex binding inhibitory receptor on mouse natu-
ral killer cells. J. Exp. Med. 199, 1245–1254.
Liao, N.S., Bix, M., Zijlstra, M., Jaenisch, R., and Raulet, D. (1991).
MHC class I deficiency: susceptibility to natural killer (NK) cells
and impaired NK activity. Science 253, 199–202.
Ljunggren, H.G., and Karre, K. (1990). In search of the ‘missing self’:
MHC molecules and NK cell recognition. Immunol. Today 11, 237–
244.
Ljunggren, H.G., Van Kaer, L., Ploegh, H.L., and Tonegawa, S. (1994).
Altered natural killer cell repertoire in Tap-1 mutant mice. Proc. Natl.
Acad. Sci. USA 91, 6520–6524.
Long, E.O. (1999). Regulation of immune responses through inhibi-
tory receptors. Annu. Rev. Immunol. 17, 875–904.
Lowin-Kropf, B., Kunz, B., Beermann, F., and Held, W. (2000). Im-
paired natural killing of MHC class I-deficient targets by NK cells ex-
pressing a catalytically inactive form of SHP-1. J. Immunol. 165,
1314–1321.
Makrigiannis, A.P., Pau, A.T., Schwartzberg, P.L., McVicar, D.W.,
Beck, T.W., and Anderson, S.K. (2002). A BAC contig map of the
Ly49 gene cluster in 129 mice reveals extensive differences in
gene content relative to C57BL/6 mice. Genomics 79, 437–444.
Marti, F., Xu, C.W., Selvakumar, A., Brent, R., Dupont, B., and King,
P.D. (1998). LCK-phosphorylated human killer cell-inhibitory recep-
tors recruit and activate phosphatidylinositol 3-kinase. Proc. Natl.
Acad. Sci. USA 95, 11810–11815.
Martin, M.P., and Carrington, M. (2005). Immunogenetics of viral in-
fections. Curr. Opin. Immunol. 17, 510–516.
Martin, M.P., Gao, X., Lee, J.H., Nelson, G.W., Detels, R., Goedert,
J.J., Buchbinder, S., Hoots, K., Vlahov, D., Trowsdale, J., et al.
(2002). Epistatic interaction between KIR3DS1 and HLA-B delays
the progression to AIDS. Nat. Genet. 31, 429–434.
Moffett-King, A. (2002). Natural killer cells and pregnancy. Nat. Rev.
Immunol. 2, 656–663.
Moretta, L., Biassoni, R., Bottino, C., Mingari, M.C., and Moretta, A.
(2000). Human NK-cell receptors. Immunol. Today 21, 420–422.
Review
257Nakamura, M.C., Linnemeyer, P.A., Niemi, E.C., Mason, L.H., Or-
taldo, J.R., Ryan, J.C., and Seaman, W.E. (1999). Mouse Ly-49D rec-
ognizes H-2Dd and activates natural killer cell cytotoxicity. J. Exp.
Med. 189, 493–500.
Nakamura, M.C., Niemi, E.C., Fisher, M.J., Shultz, L.D., Seaman,
W.E., and Ryan, J.C. (1997). Mouse Ly-49A interrupts early signaling
events in natural killer cell cytotoxicity and functionally associates
with the Shp-1 tyrosine phosphatase. J. Exp. Med. 185, 673–684.
Ohlen, C., Kling, G., Hoglund, P., Hansson, M., Scangos, G., Bieber-
ich, C., Jay, G., and Karre, K. (1989). Prevention of allogeneic bone
marrow graft rejection by H-2 transgene in donor mice. Science
246, 666–668.
Olsson, M.Y., Karre, K., and Sentman, C.L. (1995). Altered phenotype
and function of natural killer cells expressing the major histocompat-
ibility complex receptor Ly-49 in mice transgenic for its ligand. Proc.
Natl. Acad. Sci. USA 92, 1649–1653.
Olsson-Alheim, M.Y., Salcedo, M., Ljunggren, H.G., Karre, K., and
Sentman, C.L. (1997). NK cell receptor calibration: effects of MHC
class I induction on killing by Ly49Ahigh and Ly49Alow NK cells. J.
Immunol. 159, 3189–3194.
Oppenheim, D.E., Roberts, S.J., Clarke, S.L., Filler, R., Lewis, J.M.,
Tigelaar, R.E., Girardi, M., and Hayday, A.C. (2005). Sustained local-
ized expression of ligand for the activating NKG2D receptor impairs
natural cytotoxicity in vivo and reduces tumor immunosurveillance.
Nat. Immunol. 6, 928–937.
Parham, P., and McQueen, K.L. (2003). Alloreactive killer cells: hin-
drance and help for haematopoietic transplants. Nat. Rev. Immunol.
3, 108–122.
Qu, C.K., Nguyen, S., Chen, J., and Feng, G.S. (2001). Requirement
of Shp-2 tyrosine phosphatase in lymphoid and hematopoietic cell
development. Blood 97, 911–914.
Raulet, D.H., Vance, R.E., and McMahon, C.W. (2001). Regulation of
the natural killer cell receptor repertoire. Annu. Rev. Immunol. 19,
291–330.
Rosen, D.B., Bettadapura, J., Alsharifi, M., Mathew, P.A., Warren,
H.S., and Lanier, L.L. (2005). Cutting edge: lectin-like transcript-1
is a ligand for the inhibitory human NKR-P1A receptor. J. Immunol.
175, 7796–7799.
Ruggeri, L., Capanni, M., Urbani, E., Perruccio, K., Shlomchik, W.D.,
Tosti, A., Posati, S., Rogaia, D., Frassoni, F., Aversa, F., et al. (2002).
Effectiveness of donor natural killer cell alloreactivity in mismatched
hematopoietic transplants. Science 295, 2097–2100.
Salcedo, M., Diehl, A.D., Olsson-Alheim, M.Y., Sundback, J., Van
Kaer, L., Karre, K., and Ljunggren, H.G. (1997). Altered expression
of Ly49 inhibitory receptors on natural killer cells from MHC class
I-deficient mice. J. Immunol. 158, 3174–3180.
Sentman, C.L., Olsson, M.Y., and Karre, K. (1995). Missing self rec-
ognition by natural killer cells in MHC class I transgenic mice. A ‘re-
ceptor calibration’ model for how effector cells adapt to self. Semin.
Immunol. 7, 109–119.
Shultz, L.D. (1988). Pleiotropic effects of deleterious alleles at the
‘‘motheaten’’ locus. Curr. Top. Microbiol. Immunol. 137, 216–222.
Starr, T.K., Jameson, S.C., and Hogquist, K.A. (2003). Positive and
negative selection of T cells. Annu. Rev. Immunol. 21, 139–176.
Tay, C.H., Welsh, R.M., and Brutkiewicz, R.R. (1995). NK cell
response to viral infections in beta 2-microglobulin-deficient mice.
J. Immunol. 154, 780–789.
Tortorella, D., Gewurz, B.E., Furman, M.H., Schust, D.J., and Ploegh,
H.L. (2000). Viral subversion of the immune system. Annu. Rev. Im-
munol. 18, 861–926.
Tripp, C.S., Wolf, S.F., and Unanue, E.R. (1993). Interleukin 12 and tu-
mor necrosis factor alpha are costimulators of interferon gamma
production by natural killer cells in severe combined immunodefi-
ciency mice with listeriosis, and interleukin 10 is a physiologic antag-
onist. Proc. Natl. Acad. Sci. USA 90, 3725–3729.
Trowsdale, J. (2001). Genetic and functional relationships between
MHC and NK receptor genes. Immunity 15, 363–374.
Valiante, N.M., Uhrberg, M., Shilling, H.G., Lienertweidenbach, K.,
Arnett, K.L., Dandrea, A., Phillips, J.H., Lanier, L.L., and Parham, P.
(1997). Functionally and structurally distinct NK cell receptor reper-toires in the peripheral blood of two human donors. Immunity 7, 739–
751.
Vilches, C., and Parham, P. (2002). KIR: diverse, rapidly evolving re-
ceptors of innate and adaptive immunity. Annu. Rev. Immunol. 20,
217–251.
Vitale, M., Zimmer, J., Castriconi, R., Hanau, D., Donato, L., Bottino,
C., Moretta, L., de la Salle, H., and Moretta, A. (2002). Analysis of nat-
ural killer cells in TAP2-deficient patients: expression of functional
triggering receptors and evidence for the existence of inhibitory re-
ceptor(s) that prevent lysis of normal autologous cells. Blood 99,
1723–1729.
Wagtmann, N., Biassoni, R., Cantoni, C., Verdiani, S., Malnati, M.S.,
Vitale, M., Bottino, C., Moretta, L., Moretta, A., and Long, E.O. (1995).
Molecular clones of the p58 NK cell receptor reveal immunoglobulin-
related molecules with diversity in both the extra- and intracellular
domains. Immunity 2, 439–449.
Wang, J.W., Howson, J.M., Ghansah, T., Desponts, C., Ninos, J.M.,
May, S.L., Nguyen, K.H., Toyama-Sorimachi, N., and Kerr, W.G.
(2002). Influence of SHIP on the NK repertoire and allogeneic bone
marrow transplantation. Science 295, 2094–2097.
Wang, L.L., Chu, D.T., Dokun, A.O., and Yokoyama, W.M. (2000). In-
ducible expression of the gp49B inhibitory receptor on NK cells.
J. Immunol. 164, 5215–5220.
Wiemann, K., Mittrucker, H.W., Feger, U., Welte, S.A., Yokoyama,
W.M., Spies, T., Rammensee, H.G., and Steinle, A. (2005). Systemic
NKG2D down-regulation impairs NK and CD8 T cell responses
in vivo. J. Immunol. 175, 720–729.
Wu, M.F., and Raulet, D.H. (1997). Class I-deficient hemopoietic cells
and nonhemopoietic cells dominantly induce unresponsiveness of
natural killer cells to class I-deficient bone marrow cell grafts. J. Im-
munol. 158, 1628–1633.
Yokoyama, W.M. (1999). Natural killer cells. In Fundamental Immu-
nology, W.E. Paul, ed. (New York: Lippincott-Raven), pp. 575–603.
Yokoyama, W.M., and Plougastel, B.F. (2003). Immune functions en-
coded by the natural killer gene complex. Nat. Rev. Immunol. 3, 304–
316.
Yu, Y.Y.L., Kumar, V., and Bennett, M. (1992). Murine natural killer
cells and marrow graft rejection. Annu. Rev. Immunol. 10, 189–213.
Yusa, S., and Campbell, K.S. (2003). Src homology region 2-contain-
ing protein tyrosine phosphatase-2 (SHP-2) can play a direct role in
the inhibitory function of killer cell Ig-like receptors in human NK
cells. J. Immunol. 170, 4539–4547.
Zhang, S.Q., Yang, W., Kontaridis, M.I., Bivona, T.G., Wen, G., Araki,
T., Luo, J., Thompson, J.A., Schraven, B.L., Philips, M.R., and Neel,
B.G. (2004). Shp2 regulates SRC family kinase activity and Ras/Erk
activation by controlling Csk recruitment. Mol. Cell 13, 341–355.
Zimmer, J., Donato, L., Hanau, D., Cazenave, J.P., Tongio, M.M.,
Moretta, A., and de la Salle, H. (1998). Activity and phenotype of nat-
ural killer cells in peptide transporter (TAP)-deficient patients (type I
bare lymphocyte syndrome). J. Exp. Med. 187, 117–122.
